Amylyx Pharmaceuticals Inc (AMLX)
2.03
+0.03
(+1.50%)
USD |
NASDAQ |
May 03, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals SG&A Expense (Quarterly): 52.24M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 52.24M |
| September 30, 2023 | 48.72M |
| June 30, 2023 | 43.39M |
| March 31, 2023 | 44.01M |
| December 31, 2022 | 40.84M |
| September 30, 2022 | 29.94M |
| June 30, 2022 | 29.99M |
| Date | Value |
|---|---|
| March 31, 2022 | 26.35M |
| December 31, 2021 | 14.92M |
| September 30, 2021 | 10.35M |
| June 30, 2021 | 7.658M |
| March 31, 2021 | 6.004M |
| December 31, 2020 | 3.929M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.929M
Minimum
Dec 2020
52.24M
Maximum
Dec 2023
27.57M
Average
29.94M
Median
Sep 2022
SG&A Expense (Quarterly) Benchmarks
| Cassava Sciences Inc | 4.058M |
| iRhythm Technologies Inc | 100.11M |
| Bristol-Myers Squibb Co | 2.367B |
| Moderna Inc | 274.00M |
| ACADIA Pharmaceuticals Inc | 111.46M |